Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Allergan : FDA Approves BOTOX Cosmetic for the Temporary Improvement in the Appearance of Moderate to Severe Forehead Lines

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 10:30am CEST

Release date- 04102017 - DUBLIN - Today Allergan plc (NYSE: AGN) announced the FDA approval of BOTOX Cosmetic for its third indication, the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults.

This approval makes the brand the first and only neurotoxin indicated for three facial treatment areas - forehead lines, crow's feet lines and glabellar lines. 1 As the category leader, BOTOX Cosmetic is also the only neurotoxin brand to receive approval of aesthetic indications beyond glabellar lines in the U.S.

'Allergan recognizes that forehead lines are a top area of concern for patients,2' says David Nicholson, Chief Research and Development Officer at Allergan. 'Our goal in pursuing a third indication for BOTOX Cosmetic for the temporary improvement in the appearance of moderate to severe forehead lines was based on our desire to study the patient selection, dosing and injection pattern to help provide optimal treatment outcomes.'

The BOTOX Cosmetic story began in 2002 when the brand helped establish the aesthetic market with its first FDA approval to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). The momentum continued in 2013 when BOTOX Cosmetic was approved for the temporary improvement in the appearance of moderate to severe crow's feet lines.3,4 The addition of this third indication furthers Allergan's mission to continue providing patients and physicians with products designed to address specific patient needs.

'As a physician, I've been using BOTOX Cosmetic since it was FDA approved in 2002,3 but for years my patients have also inquired about how to treat forehead lines. With this latest indication for BOTOX Cosmetic, I have an FDA-approved product I already know and trust, that can improve the appearance of the forehead,1' says Dr. Steven Fagien, an Oculoplastic Surgeon in Boca Raton, Florida and lead clinical trial investigator. 'I am proud to have worked closely with Allergan to establish criteria for proper patient selection, dosing and injection pattern for forehead line treatment and am pleased to see that the company is providing extensive injector training to help ensure optimal results.'

'Few products have the level of impact that BOTOX Cosmetic has had on the medical facial aesthetics industry,' said David Moatazedi, Senior Vice President U.S. Medical Aesthetics at Allergan. 'BOTOX Cosmetic is the brand that created a new category in facial aesthetics with its first FDA approval 15 years ago. 3 Since then it has continued to be the leading neurotoxin treatment and the world's number one selling product of its kind.' 5

In clinical trials, BOTOX Cosmetic demonstrated efficacy compared with placebo in the reduction of the severity of forehead lines, as assessed by both the investigator and the subject at Day 30 (primary endpoint): 61% of subjects in study one and 46% of subjects in study two met the primary endpoint compared with placebo (0% in Study one and 1% in Study two). Similar response rates were seen across three treatments cycles with BOTOXCosmetic.1

Approved for use in over 75 countries, BOTOX Cosmetic is the most widely researched and studied treatment of its kind. 6,7 The safety and efficacy have been evaluated in Allergan clinical studies and described in nearly 500 peer-reviewed articles in scientific and medical journals. 7,8 BOTOX Cosmetic is manufactured in a state-of-the art facility under strict quality and safety standards.

Approved Uses

BOTOX Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.


BOTOX Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOXCosmetic:

Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.

Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing

BOTOX Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.

BOTOX Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOXCosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX Cosmetic if you: are allergic to any of the ingredients in BOTOX Cosmetic; had an allergic reaction to any other botulinum toxin product; have a skin infection at the planned injection site.

Tell your doctor about all your muscle or nerve conditions

Tell your doctor about all your medical conditions, including: if you are or plan to become pregnant or breast feed.

Tell your doctor about all the medicines you take. Using BOTOXCosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

The most common side effects of BOTOX Cosmetic include: discomfort or pain at the injection site; headache and eye problems: double vision, blurred vision, drooping eyelids and eyebrows, and swelling of your eyelids.

For more information refer to the Medication Guide or talk with your doctor.

To report a side effect, please call Allergan at 1-800-433-8871.


BOTOX Cosmetic Prescribing Information 2017.

Data On File Allergan, Inc.; Facial Injectables Patient Records Tracking Study Neurotoxins, 2016.

Department of Health and Human Services FDA-Approval Letter for BOTOXCosmetic for Glabellar Lines, 2002.

FDA News Release, BOTOX Cosmetic FDA-approval letter for Crow's Feet (ttp://www.fda.gov/NewsEvents/...), 2013.

Data On File Allergan, Inc.; 2016 A&U Neurotoxins Data on File, BOTOXCosmetic 2015 WW

Leader in Cosmetic NM Market, 2015.

BOTOX Cosmetic Website, (ttps://www.botoxcosmetic.com/...)

Data On File Allergan, Inc.; Peer-Reviewed Articles, 2015.

Data On File Allergan, Inc.; Patient Clinicals, 2015.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model - Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

Forward Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan'scurrent perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDAapprovals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergandisclaims any intent or obligation to update these forward-looking statements.


Daphne Karydas

Tel: (862) 261-8006

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
02:01pALLERGAN : Receives FDA Fast Track Designation for AGN-241751 for the Treatment ..
01:37pALLERGAN PLC : Wired News – Allergan’ and Molecular Partners’ Abicipar Meets Pri..
12:16pALLERGAN : Pre-Market Research Reports on Generic Drugs Stocks -- Tricida, Zoeti..
11:38aALLERGAN : Court denies appeal in Mohawk case, clarifies IPR's role
07/20ALLERGAN : AGN), Molecular Partners Announce Two Positive Phase 3 Clinical Trial..
07/20ALLERGAN : announce clinical trial success for abicipar
07/20ALLERGAN : abicipar pegol non-inferior to Lucentis, but increases inflammation
07/20ALLERGAN : Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Dro..
07/20IRONWOOD PHARMACEUTICALS : Initiates Phase IIIb Study of Linaclotide in Adult Pa..
07/20ALLERGAN : Researchers from Allergan Describe Findings in Erythema (Reduction in..
More news
News from SeekingAlpha
08:51aAllergan's AGN-241751 Fast Track'd in U.S. for MDD 
01:20aALLERGAN : Inflammation Is The Reason Investors Did Not React Well To Abicipar R.. 
07/213 THINGS IN BIOTECH, JULY 21 : Does CTI Really Deserve To Tank? 
07/20Allergan strikes out with sovereign nation scheme to protect patents 
07/20Allergan holds off Novartis' generic version of Combigan 
Financials ($)
Sales 2018 15 346 M
EBIT 2018 7 408 M
Net income 2018 -1 152 M
Debt 2018 23 173 M
Yield 2018 1,60%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,31x
EV / Sales 2019 4,99x
Capitalization 58 248 M
Duration : Period :
Allergan plc Technical Analysis Chart | 4-Traders
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 207 $
Spread / Average Target 20%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC5.02%58 790
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-0.24%206 705
ROCHE HOLDING LTD.-5.07%200 737
MERCK AND COMPANY11.11%168 171